Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-25T16:27:46.125Z Has data issue: false hasContentIssue false

The ‘Top 10’ Challenges for Health Technology Assessment: INAHTA Viewpoint

Published online by Cambridge University Press:  28 November 2019

Brian O'Rourke
Affiliation:
Canadian Agency for Drugs and Technologies in Health, 865 Carling Avenue, Suite 600, K1S 5S8Ottawa, Ontario, Canada
Sophie Söderholm Werkö
Affiliation:
Swedish Agency for Health Technology Assessment and Assessment of Social Services, P.O. Box 6163, S-102 33 Stockholm, Sweden
Tracy Merlin
Affiliation:
Adelaide Health Technology Assessment, The University of Adelaide, School of Public Health, Level 9, Adelaide Health and Medical Sciences Building, Cnr Nth Terrace and George Street, Adelaide, South Australia
Li Ying Huang
Affiliation:
Center for Drug Evaluation, 3F, No.465, Sec.6, Zhongxiao E. Rd., Taipei 11557, Taiwan, Republic of China
Tara Schuller
Affiliation:
INAHTA Secretariat, 1200, 10405 Jasper Avenue NW, Edmonton, AB, Canada

Abstract

The International Network of Agencies for Health Technology Assessment (INAHTA) spans the globe as a network of 50 publicly-funded health technology assessment (HTA) agencies supporting health system decision making for 1.4 billion people in thirty countries. Agency members are non-profit HTA organizations that are part of, or directly support, regional or national governments. Recently, INAHTA surveyed its members to gather perspectives from agency leadership on the most important issues in HTA today. This paper describes the top 10 challenges identified by INAHTA members. Addressing these challenges requires a call for action from INAHTA member agencies and the many other actors involved in the HTA ecosystem. In opening this call for action, INAHTA will lead the way; however, a comprehensive undertaking from all players is needed to effectively address these challenges and to continue to evolve HTA in its role as a strong and effective contributor to health systems.

Type
Perspective
Copyright
Copyright © Cambridge University Press 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Hailey, D, Menon, D (1999) A short history of INAHTA. Int J Technol Assess Health Care 15(1), 236242.CrossRefGoogle Scholar
2.International Network of Agencies for Health Technology Assessment (INAHTA) (2017) INAHTA Strategic Plan 2017–2020. Available at: http://www.inahta.org/wp-content/uploads/2019/02/INAHTA-Strategic-Plan-2017-2020.pdf. Accessed 2019.Google Scholar
3.World Bank (2019) World Bank Country and Lending Groups. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed 2019.Google Scholar
4.Atkins, D, Best, D, Briss, PA, Eccles, M et al. (2004) Grade Working Group grading quality of evidence and strength of recommendations. BMJ 328(7454), 1490.Google Scholar
5.Schuller, T, Söderholm Werkö, S (2017) Insights from the front lines: A collection of stories of HTA impact from INAHTA member agencies. Int J Technol Assess Health Care 33(4), 409410.CrossRefGoogle ScholarPubMed
6.Kaltenthaler, E, Cooper, K, Pandor, A et al. (2016). The use of rapid review methods in health technology assessments: 3 case studies. BMC Med Res Methodol 16(1), 108.CrossRefGoogle ScholarPubMed
7.Khangura, S, Polisena, J, Clifford, TJ et al. (2014). Rapid review: An emerging approach to evidence synthesis in health technology assessment. Int J Technol Assess Health Care 30(1), 2027.CrossRefGoogle ScholarPubMed
8.Merlin, T, Tamblyn, D, Ellery, B (2014) What's in a name? Developing definitions for common health technology assessment product types of the international network of agencies for health technology assessment (INAHTA). Int J Technol Assess Health Care 30(4), 430437.CrossRefGoogle Scholar